To compare the mobilisation efficiency of biosimilar filgrastim, originator filgrastim, and lenograstim in patients with multiple myeloma in first line therapy

Trial Profile

To compare the mobilisation efficiency of biosimilar filgrastim, originator filgrastim, and lenograstim in patients with multiple myeloma in first line therapy

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Filgrastim (Primary) ; Lenograstim (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Nov 2017 New trial record
    • 01 Oct 2017 Results published in the Transfusion
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top